While Illinois lawmakers consider a “Health Care Availability and Access Board” (sometimes referred to as a prescription drug affordability board or PDAB), these boards are really code for government price-setting. Illinoisans should be concerned.
Patients in Illinois face high health care costs and coverage barriers, but a price-setting board like the one proposed in HB 4472 is not the solution.
Here’s why:
- Government price-setting could limit access to critical medicines by inserting bureaucrats between patients and doctors.
- Insurance companies and pharmacy benefit managers (PBMs) are not currently required to share the discounts and rebates provided by biopharmaceutical manufacturers directly with patients. This bill does not address this issue.
- PBMs and their health insurance companies control what patients pay out-of-pocket, not manufacturers.
- Similar policies at the federal level (like the Inflation Reduction Act) — already jeopardize the development of new medicines — and these boards could have similar negative effects.
- There’s no system for checks and balances. Proponents of the board haven’t articulated how they will monitor and track alleged savings in any state.
PDABs in Maryland and Colorado are spending millions of dollars creating new bureaucratic positions and red tape — without helping one patient or saving one cent since 2019. Illinois shouldn’t be another open checkbook along the way to waste funds on misguided schemes.
Several patient groups across the country have publicly shared their concern that PDABs may reduce access to medicines. And they’ve been joined by voices across the supply chain including hospitals, insurers, and doctors. These voices expose real and unfortunate potential consequences to government price-setting and the establishment of these boards.
Patients need real leadership from everyone involved in our health care system to make it better. That’s why our companies are calling for policymakers to join us in supporting common-sense reforms to make insurance work like it was intended and help make sure patients can access and afford the medicines their doctors prescribe. For more information on the harm these boards cause and other solutions lawmakers can pursue to lower costs and increase health care access, visit PhRMA.org/States.
Stami Turk
Stami Williams is Director of State Public Affairs where she oversees earned and paid media efforts in several regions across the country. Stami received her M.P.S. from George Washington University, where she remains an adjunct professor with undergraduate studies at Kennesaw State University in Georgia.
Stami Turk
What AARP isn’t telling seniors about MFN
Policymakers should improve patient access and reject price controls
CMS proposal could discourage patient-centered innovation
Nearly 1 in 4 patients initially denied access to IRA medicines
Government price setting won’t help patients in Illinois
Government Price Setting
State Policy
Government price setting won’t help patients in Illinois
Government price setting won’t help patients in Illinois